These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1778323)

  • 1. Introduction to the International Symposium on Pertussis Evaluation and Research on Acellular Pertussis Vaccines.
    Oya A
    Dev Biol Stand; 1991; 73():3-4. PubMed ID: 1778323
    [No Abstract]   [Full Text] [Related]  

  • 2. Japanese clinical experiences with acellular pertussis vaccines.
    Kimura M
    Dev Biol Stand; 1991; 73():5-9. PubMed ID: 1778333
    [No Abstract]   [Full Text] [Related]  

  • 3. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas.
    Ohkuni H; Yabiku M; Togawa M; Fukai K; Yosida I; Minekawa Y; Kitamura T
    Dev Biol Stand; 1991; 73():43-9. PubMed ID: 1778332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan.
    Isomura S
    Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
    Kato T; Kaku H; Arimoto Y
    Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of pertussis and use of acellular pertussis vaccines in Japan.
    Kuno-Sakai H; Kimura M
    Dev Biol Stand; 1997; 89():331-2. PubMed ID: 9272368
    [No Abstract]   [Full Text] [Related]  

  • 7. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Kuno-Sakai H; Kimura M; Watanabe H
    Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Swedish efficacy trial of acellular pertussis vaccines--update and time for reflection.
    Olin P
    Dev Biol Stand; 1991; 73():33-6. PubMed ID: 1778327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis.
    Kimura M; Kuno-Sakai H
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):263-73. PubMed ID: 3508651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese experience with 60 million doses of acellular pertussis vaccines.
    Sato H
    Dev Biol Stand; 1997; 89():327-9. PubMed ID: 9272367
    [No Abstract]   [Full Text] [Related]  

  • 11. International symposium on pertussis evaluation and research on acellular pertussis vaccines. National Institute of Health in Tokyo and International Association of Biological Standardization. 14-15 September 1990 at Shizuoka, Japan.
    Biologicals; 1991 Apr; 19(2):145-9. PubMed ID: 1888495
    [No Abstract]   [Full Text] [Related]  

  • 12. Acellular pertussis vaccines in Japan: past, present and future.
    Watanabe M; Nagai M
    Expert Rev Vaccines; 2005 Apr; 4(2):173-84. PubMed ID: 15889991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has the change to acellular pertussis vaccine improved or worsened pertussis control?
    Halperin SA; De Serres G
    CMAJ; 2006 Nov; 175(10):1227. PubMed ID: 17098952
    [No Abstract]   [Full Text] [Related]  

  • 15. Pertussis vaccine acceptance rates and incidence of pertussis in forty seven districts (prefectures) in Japan since 1977.
    Kimura M; Kuno-Sakai H; Ozaki K
    Tokai J Exp Clin Med; 1988; 13 Suppl():9-13. PubMed ID: 3273621
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical studies on efficacy and safety of acellular pertussis vaccine.
    Isomura S
    Tokai J Exp Clin Med; 1988; 13 Suppl():39-43. PubMed ID: 3078809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Pichichero ME; Decker MD
    Biologicals; 2005 Mar; 33(1):59. PubMed ID: 15713557
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of currently available Japanese acellular pertussis vaccines and future problems.
    Kamiya H; Nii R
    Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Academy of Pediatrics Committee on Infectious Diseases: The status of acellular pertussis vaccines: current perspective.
    Pediatrics; 1991 Aug; 88(2):401-5. PubMed ID: 1861950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.